BLIS K12 Receives “No Objection” GRAS Letter From FDA

635914720924384696taste.jpg

19 Feb 2016 --- Oral-health probiotic BLIS K12 has received a “Letter of No Objection” from the US Food and Drink Administration (FDA) for its self-affirmed notification of Generally Recognized As Safe (GRAS) status.

The patented probiotic strain of Streptococcus salivarius, BLIS K12, has been studied for benefits to ear and throat health in children and adults, including reducing incidence of halitosis and Streptococal pharyngitis.

 

BLIS K12 developer Blis Technologies (Dunedin, New Zealand) and North America distributor Stratum Nutrition (Saint Charles, MO) celebrated the “No Objection” GRAS status as key to opening more markets for the probiotic:

 

“It adds a new level of credibility for BLIS K12 and puts the conversations with larger consumer food and beverage companies in the US on a stronger footing,” said Peter Fennessy, board chairman, Blis Technologies.

 

“Many of those companies are, quite rightly, risk averse. Therefore, having the non-objection notification from the FDA offers an additional level of confidence and makes it clearer where BLIS K12 fits within the category,” Fennessy added.

 

Jeremy Moore, managing director of Stratum Nutrition, added, “Very few ingredients in this space go to this level, so it is a definite feather in the cap for Blis.”

 

Through the GRAS program, companies may submit their determination, supported by research and expert review, that a specific ingredient is Generally Recognized As Safe. The Letter of No Objection means that the FDA has reviewed the data and has no questions regarding the notice submitted.

RELATED ARTICLES
Homepicture

Seventure Partners’ microbiome portfolio nears critical milestones 

18 Dec 2017 Seventure Partners, one of Europe’s ...

Homepicture

Vitafoods Europe to examine mainstreaming of personalized nutrition

13 Dec 2017 One of the major issues to be discussed at ...

Homepicture

Frutarom finalizes AB-Fortis micro-encapsulation technology acquisition

13 Dec 2017 Frutarom has acquired AB-Fortis activities, ...

Homepicture

Kappa Bioscience moves to expand vitamin K2 presence in US with new appointments

13 Dec 2017 Kappa Bioscience AS, maker of K2Vital vitamin K2 ...

Homepicture

Enzymotec and Frutarom merger gets shareholder green light

12 Dec 2017 The shareholders of Israeli specialty chemicals ...